Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HIV-1 virus-like particle vaccine
- Development stage
- Preclinical
- Lead developer
- AdaptVac
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
The HIV-1 virus-like particle vaccine is a preclinical-stage vaccine candidate being developed by AdaptVac, a Danish biotechnology company. Utilizing their proprietary modular capsid virus-like particle (cVLP) platform, the vaccine is engineered to display HIV-1 envelope glycoprotein antigens on the surface of cVLP scaffolds. This architecture is designed to mimic the repetitive structure of a virus, thereby eliciting a robust and targeted immune response against HIV-1. The primary objective of the candidate is the prevention or control of HIV-1 infection and the progression to AIDS.
- Other names
- HIV-1 cVLP vaccineHIV1 cVLP vaccineHIV 1 cVLP vaccine
02
Targets
CD4+ T-cell receptor recognizing HIV-1 Envelope-derived peptides presented by MHC class IIBCR-HIV-Env (HIV-1 envelope-specific B-cell receptor)Human immunodeficiency virus type 1 envelope glycoprotein 140 trimerCD8+ T-cell receptor recognizing HIV-1 envelope glycoprotein-derived peptides
Beyond the preview
Go deeper on HIV-1 virus-like particle vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HIV-1 virus-like particle vaccine.